Mussini C - Search Results

1

Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment.

Mocroft A, Lundgren J, Gerstoft J, Rasmussen LD, Bhagani S, Aho I, Pradier C, Bogner JR, Mussini C, Uberti Foppa C, Maltez F, Laguno M, Wandeler G, Falconer K, Trofimova T, Borodulina E, Jevtovic D, Bakowska E, Kase K, Kyselyova G, Haubrich R, Rockstroh JK, Peters L; EuroSIDA Study. Mocroft A, et al. Among authors: mussini c. Clin Infect Dis. 2020 May 6;70(10):2131-2140. doi: 10.1093/cid/ciz601. Clin Infect Dis. 2020. PMID: 31504296 Free article.

2

Loss to follow-up in an international, multicentre observational study.

Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD; EuroSIDA study group. Mocroft A, et al. HIV Med. 2008 May;9(5):261-9. doi: 10.1111/j.1468-1293.2008.00557.x. HIV Med. 2008. PMID: 18400074 Free article.

3

Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.

Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group. Bannister WP, et al. J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33. doi: 10.1097/QAI.0b013e31817ae5c0. J Acquir Immune Defic Syndr. 2008. PMID: 18545152 Clinical Trial.

4

Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.

Podlekareva D, Mocroft A, Kirk O, Reiss P, Aldins P, Katlama C, Kovari H, Stellbrink HJ, D'Arminio Monforte A, Lundgren JD; Eurosida Study Group. Podlekareva D, et al. Scand J Infect Dis. 2008;40(11-12):908-13. doi: 10.1080/00365540802227094. Scand J Infect Dis. 2008. PMID: 18609197

5

Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe.

Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J; EuroSIDA Study Group. Soriano V, et al. J Infect Dis. 2008 Nov 1;198(9):1337-44. doi: 10.1086/592171. J Infect Dis. 2008. PMID: 18767985 Free article.

6

Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.

Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD; EuroSIDA Study Group. Cozzi-Lepri A, et al. AIDS. 2008 Oct 18;22(16):2187-98. doi: 10.1097/QAD.0b013e328310e04f. AIDS. 2008. PMID: 18832882

7

The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results.

Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, Lundgren JD, Kirk O; EuroSIDA Study Group. Podlekareva D, et al. Cent Eur J Public Health. 2008 Sep;16(3):99-105. doi: 10.21101/cejph.a3490. Cent Eur J Public Health. 2008. PMID: 18935770 Review.

8

Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression.

Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD; EuroSIDA Study Group. Peters L, et al. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):457-63. doi: 10.1097/qai.0b013e318198a0e1. J Acquir Immune Defic Syndr. 2009. PMID: 19360931

9

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.

Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A; Nevirapine Toxicity Multicohort Collaboration. Kesselring AM, et al. AIDS. 2009 Aug 24;23(13):1689-99. doi: 10.1097/QAD.0b013e32832d3b54. AIDS. 2009. PMID: 19487907

10

Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.

Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups. Morsica G, et al. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81. doi: 10.1097/QAI.0b013e3181add592. J Acquir Immune Defic Syndr. 2009. PMID: 19590432

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

776 results

Search Page

Filters